Tomasz Sablinski

See the following -

Chip Away At The Stone: REMOTE, Transparency Life Sciences

Lisa Henderson | Applied Clinical Trials | February 1, 2013

(This blog is part 2 of my interview with Tomasz Sablinski, MD, PhD, Founder and CEO of Transparency Life Sciences. As noted in my first blog, Sablinski’s company announced it was the first company to have an IND cleared using a crowdsourced protocol. [...] Read More »

FDA Clears IND For First Clinical Trial Protocol Developed Using Crowdsourcing

Press Release | Transparency Life Sciences (TLS) | December 18, 2012

Transparency Life Sciences, LLC (TLS), the world's first drug development company based on open innovation, today announced that its Investigational New Drug Application (IND) to assess lisinopril as an adjunctive therapy for multiple sclerosis (MS) has been cleared by the US Food and Drug Administration (FDA). Read More »

Let’s Build A Drug! Biopharma Startup Launches Crowdsourcing Tool To Pick Compounds

Stephanie Baum | MedCity News | October 24, 2012

A biopharma startup believes that when it comes to deciding what conditions it should develop drugs to treat, the decision should be left to a public vote. Read More »

Re-thinking Clinical Trials For The World Of Crowdsourcing

Laurie Halloran | Xconomy | April 16, 2013

Disruption isn’t a word normally associated with clinical drug development, but nevertheless it is coming. [...] There are signals that drug development is starting to catch up with the general trend toward open collaboration and innovation. This trend is enabling tremendous advances in other industries, so why not ours? Read More »

Transparency Life Sciences Awarded $1.4 Million NCATS SBIR Grant To Conduct Innovative Trial Of Lisinopril In Multiple Sclerosis

Press Release | Transparency Life Sciences | September 8, 2014

Transparency Life Sciences, LLC (TLS)...today announced that it has received a Small Business Innovation Research (SBIR) program grant to fund a Phase 2a proof-of-concept study testing the utility of the ACE inhibitor lisinopril as an adjunctive therapy for multiple sclerosis (MS).

Read More »

Transparency Life Sciences Launches Indication Finder™ Crowdsourcing Tool For Drug Repurposing

Press Release | Transparency Life Sciences (TLS) | October 24, 2012

Transparency Life Sciences (TLS), the world's first drug development company based on open innovation, today announced the launch of Indication Finder™, a survey-based crowdsourcing tool designed to identify promising new indications for existing drug candidates. Read More »

Trial Designed With Crowd Input Gets FDA Signoff

Marc Iskowitz | MM&M | December 28, 2012

What's been called the first clinical study protocol developed using crowdsourcing methods received the FDA's imprimatur earlier this month. The agency approved Transparency Life Sciences' IND for a clinical trial designed to test a generic blood-pressure medication, ACE inhibitor lisinopril, in patients with relapsing remitting multiple sclerosis. Read More »